Fig. 3
From: COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis
COMMD3 loss causes aggressive tumour formation in breast cancer. A. Box plot of COMMD3 transcripts across cell lines grouped in the basal A (red), basal B (grey) and luminal (blue) subgroups based on annotation data from Neve et al. [43]. A p value shows difference between basal and luminal determined by ANOVA test. These data were derived from Gene expression-based Outcome for Breast cancer Online (GOBA) analysis tool [44]. B. Western blot analysis of COMMD3 protein levels in a panel of human breast cancer lines representing the different subtypes of breast cancer. COX-IV used a loading control. C. Western blot analysis showing COMMD3 protein levels in different subcellular fractions of breast cancer cell lines. Vinculin and H3 were used as markers of the different fractions. Cytoplasmic (1), and nucleoplasmic (2) and chromatin (3). D. 4T07 cells were transduced with pGIPz shControl or two different shCOMMD3 hairpin sequences and selected for stable expression. The efficiency of COMMD3 depletion was assessed by western blotting. E. 4T07 cells expressing the shcontrol or shCommd3 #1 were plated on GFR matrigel in 2% FCS and grown for 14 days prior to imaging. F. Tumour growth curves after implantation of 4T07 cells into the inguinal mammary gland of female Balb/C mice. Bars show mean ± SD. N = 6 mice in each group, ANOVA with Holm-Sidak test, P value at day 19: shCon vs. shCommd3#1: 0.0444; shCon vs. shCommd3#2: 0.0047. G. Representative images of gross morphology of excised tumours at endpoint. H. Mouse survival after implantation of 1 × 105 cells into fat pads of female Balb/C mice. N = 6 mice in each group. Hazard Ratio (logrank) for shCon vs. shCommd3#1: 0.3070 (95% CI: 0.05854 to 1.611), p value: 0.1626; shCon vs. shCommd3#2: 0.4682 (95% CI: 0.07892 to 2.778), p value: 0.3912. Median survival of each group: shcon: undefined; shCommd3#1: 63.5 days; shCommd3#2: 77.5 days